Literature DB >> 28844707

Are we reproducible in measurement of NET liver metastasis?

Salma Moalla1, Julia Arfi Rouche2, Stéphanie Foulon3, Caroline Caramella1, Nils Ternes3, David Planchard4, Diane Goere5, Michel Ducreux4, Jean Yves Scoazec6, Frederic Deschamps7, Clarisse Dromain1, Eric Baudin8.   

Abstract

Accurate measurement of well-differentiated neuroendocrine tumours (NET) liver metastases is critical to determine tumour slope and to assess treatment efficacy. Our objectives were to determine which CT or MRI sequence is the most reproducible to measure NET liver metastases and to assess the percentage of variability of measurements. Intra and inter-observer variability were studied on triphasic abdominal CT or liver MRI in 22 and 32 NET patients respectively. Patients were treatment-naïve or under somatostatin analogues. A maximum of 5 liver target lesions per patient was defined and three radiologists measured them on each sequence. Reproducibility were analysed by calculating the relative variation (RV) as defined by RECIST criteria. We analysed 1656 target measurements for CT and 3384 for MRI. Intra-observers RV were better than inter-observers. T2 for MRI and portal-phase for CT were associated with the lowest measurement variability. The MRI sequence offering the best intra and inter-observer reproducibility is the T2W-sequence. MRI allows more reproducible measurement than CT (inter-observer RV <20% in 96.8% for MRI and 81% for CT). Our study demonstrates intermediate to high imaging reproducibility of liver metastases measurements in NET patients. Non-enhanced MRI should be preferred to triphasic-CT for follow-up, assessment of treatment and trials.
Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metastasis; Neuroendocrine tumor; RECIST; Reproducibility

Mesh:

Substances:

Year:  2017        PMID: 28844707     DOI: 10.1016/j.dld.2017.05.015

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  2 in total

Review 1.  Are recist criteria adequate in assessing the response to therapy in metastatic NEN?

Authors:  Marie-Pierre Vullierme; Philippe Ruszniewski; Louis de Mestier
Journal:  Rev Endocr Metab Disord       Date:  2021-04-19       Impact factor: 9.306

2.  Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients.

Authors:  Olof Pettersson; Katarzyna Fröss-Baron; Joakim Crona; Anders Sundin
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.